

Authors: Rachel Allen, PharmD; Aaron Effoe, PharmD; Kara Birrer, PharmD; David Motola, MD
 Co-Authors: Gregory Semon, DO
 Editors: Michael L. Cheatham, MD; Chadwick P. Smith, MD
 Approved: 11/06/2013 Revised 12/4/2014, 11/7/2021, 2/23/2024

SUMMARY

Thromboelastography (TEG) is a whole-blood coagulation test that has been shown to decrease blood product use and mortality when used to evaluate the coagulation cascade and guide administration of blood products during hemostatic resuscitation in the trauma setting.

RECOMMENDATIONS

Level 1

- None

Level 2

- TEG may be used to screen patients for coagulopathy in the following situations:
 - Blunt or penetrating trauma patients who arrive in hemorrhagic shock
 - Clinical suspicion for hemorrhage or coagulopathy
 - Patients receiving massive transfusion protocol to guide or discontinue product therapy

Level 3

- TEG should be repeated as needed to guide blood product administration until the patient's coagulopathy is corrected
- TEG may be used to guide blood product administration in bleeding patients as follows:

Trauma Patients (TEG 6s)	
R _{CK} time > 9.1	Transfuse fresh frozen plasma (FFP)
MA _{CFF} < 15	Transfuse platelets
MA _{CRT} < 52	Transfuse cryoprecipitate +/- platelets
LY 30 > 2.6	Administer tranexamic acid

Non-Trauma Patients (TEG 5000)	
R time > 8	Transfuse FFP
K-time > 3	Transfuse cryoprecipitate
α angle < 53	Transfuse cryoprecipitate +/- platelets
MA < 51	Transfuse platelets

INTRODUCTION

TEG was developed in 1948 by Hellmut Hartert in Heidelberg, Germany as a test to detect clotting factor deficiencies (1). It was not until 1967 when Hardaway used TEG to describe the coagulation changes seen in combat casualties suffering hemorrhagic shock in Vietnam. Its availability in the United States was limited until the 1980's, when the addition of disposable components, tissue activators, and computerized software made the test more practical,

LEVEL OF RECOMMENDATION DEFINITIONS

- **Level 1:** Supported by multiple, prospective randomized clinical trials or strong prospective, non-randomized evidence if randomized testing is inappropriate.
- **Level 2:** Supported by prospective data or a preponderance of strong retrospective evidence.
- **Level 3:** Supported by retrospective data or expert opinion.

DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care practices based on the medical literature and clinical expertise at the time of development. They should not be considered to be accepted protocol or policy, nor are intended to replace clinical judgment or dictate care of individual patients.

reproducible, and timely. TEG is designed to assist the clinician in identifying coagulopathy as demonstrated by deranged clot formation in a whole blood sample. If coagulopathy is identified, the TEG results will point to the specific therapy to treat it as identified by the abnormalities in the clot tracing.

To perform a TEG, an aliquot of blood is placed into a cup that has been pre-warmed to 37°C. A pin is immersed in the sample and attached by a wire to a transducer (Figure 1). The cup rotates around the pin. As clot begins to form, the pin and cup are joined by formation of the clot causing the pin and cup to rotate together. This change in tension is detected by a transducer, which produces a graphical plot of clot strength on the Y-axis versus time on the X-axis. Different activators may be used to induce the clotting cascade. Conventional TEG is activated with kaolin, which initiates the intrinsic pathway, resulting in the "reaction time" or "R-time" that is analogous to activated partial thromboplastin time (aPTT) and International Normalized Ratio (INR). This denotes the amount of time it takes the blood to begin forming a clot. It is indicative of the initiation phase of clotting factor activation. Rapid TEG (r-TEG) utilizes tissue factor (TF) in addition to kaolin, activating both the intrinsic and extrinsic pathways and producing the activated clotting time or TEG-ACT.




Figure 1: The TEG mechanism

The next data point encountered is known as the "kinetic time" or "K-time". The slope of the curve caused by that movement is called the "alpha angle". These two values represent the rate at which the clot strengthens and are most representative of thrombin cleaving available fibrinogen and fibrin. The maximum height of the curve is called the "maximum amplitude", or MA. This is a result of maximal fibrin-platelet interaction. The termination stage begins with fibrinolytic dissolution of the fibrin-platelet bond between the pin and the cup. The percentage return to baseline of the total MA at 30 minutes is the "lysis at 30 minutes", or "LY 30".




Figure 2: TEG tracing with associated data points

TEG is thus a test of whole blood coagulation that assesses multiple points in the clotting cascade and can identify a variety of coagulation deficits. Computer software is available that allows the tracing to be displayed electronically, as the test is performed, at remote locations such as an operating room or trauma bay. Initial results are typically available within 15 minutes with the final tracing becoming available within 45-60 minutes.

There are several variations of the TEG system with the TEG 5000 being the most used system. The TEG 6s system was introduced in 2017 and provides a more reliable point of care test compared to the TEG 5000. With the TEG 6s system, blood will vibrate at a fixed frequency inside an automated 4 channel system using resonant frequency viscoelastic measurements (2). This process eliminates the need for pipetting of blood as previously required with the TEG 5000 system. The increased accuracy and ease of use with the TEG 6s system has led to it being the preferred coagulopathy detection system in the trauma population. For non-trauma patients, the TEG 5000 should still be used as the standard system for detecting coagulopathy due to limited studies outside of the trauma population.

LITERATURE REVIEW

The widespread use of TEG in the United States began in the 1980's as an important tool during orthotopic liver transplantation (3). Liver transplantation often requires massive blood transfusion and the complex coagulopathies that occur during the anhepatic and post-reperfusion stages. TEG-guided transfusion algorithms were shown to greatly reduce the requirements for blood product transfusion (3). By the 1990's, TEG was being applied to cardiac surgery which consumes 20% of all blood products in the United States (4). Ten percent of patients have excessive bleeding following cardiopulmonary bypass, 50% of these secondary to coagulopathy. This may occur due to inadequate heparin reversal or the effects of the cardiopulmonary bypass circuit on platelets. The alpha angle was shown to be strongly correlated with total blood loss. Speiss et al., in an analysis of 1079 coronary artery bypass graft (CABG) patients, demonstrated that a TEG-guided algorithm was shown to decrease overall peri-operative transfusion requirements with the number of re-explorations for bleeding decreasing from 5.7% to 1.5% (4). Ak et al. randomized 224 CABG patients to a clinician-directed transfusion strategy or a TEG-guided algorithm (5). Overall, there was no difference in blood loss, packed red blood cells transfused, or clinical outcome. However, the TEG group received fewer transfusions of platelets, fresh frozen plasma (FFP), and tranexamic acid and had significant cost savings.

With its ability to rapidly detect coagulopathies and provide guidance for blood product transfusion, TEG has been applied to the resuscitation of traumatically injured patients. In the setting of massive hemorrhage, the body rapidly activates coagulation pathways to prevent ongoing blood loss. However, a delicate balance must occur to prevent a prothrombotic state, which has complications such as deep venous thrombosis and pulmonary embolism. This results in the so-called "coagulopathy of trauma". Studies have shown that as many as 25% of severely injured trauma patients are coagulopathic upon admission to the emergency department (6-9). In those injured enough to require massive transfusion protocol (MTP), that number has been shown to reach as high as 75% (8).

Cohen et al. examined 203 trauma patients with serial prothrombin time (PT), partial thromboplastin time (PTT), Factor Va, Factor VIIIa, protein C, tissue plasminogen activator (t-PA), and D-dimer levels at arrival, 6 hours, 12 hours, and 24 hours (10). Patients with tissue hypoperfusion and severe traumatic injury showed strong activation of protein C which was associated with coagulopathy. Furthermore, elevated activated protein C levels were significantly associated with organ failure, infection, and death.

The PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study evaluated 1198 trauma patients of whom 41.6% were coagulopathic (11). While also implicating protein C, depletion of Factors I, II, V, VII, VIII, IX, and X was additionally identified in these patients.

Trauma surgeons have traditionally employed conventional coagulation tests (CCTs) to evaluate trauma patients for coagulopathy. These include PT, PTT, and INR, tests that were developed to guide coumadin and heparin therapy as well as test for clotting factor deficiencies. Platelet count is useful in determining the number of circulating platelets, but does not assess platelet function. TEG has thus emerged as a test that can provide an accurate and real-time picture of whole blood coagulation in the bleeding trauma patient. In one of the first major studies in trauma, only TEG and Injury Severity Score (ISS) were found to be predictive of blood transfusion in this population (12).

In a porcine model, Martini et al. examined PT, PTT, activated clotting time (ACT), and TEG after induced hypothermia and hemorrhagic shock (13). Hypothermia was found to inhibit clotting times and clotting rate whereas hemorrhage impaired clot strength. Combining hypothermia with hemorrhage impaired all these clotting parameters. PT and PTT were not sensitive whereas ACT was not specific in detecting coagulation defects. Only

TEG differentiated the mechanism related to clotting abnormalities, leading the authors to conclude that TEG allows better focused treatment of coagulopathy associated with hypothermia and hemorrhagic shock.

Lier et al. performed a systematic search of topics of trauma and coagulation as well as therapeutic options. The acute coagulopathy of trauma impaired survival, correlated independently with an eight-fold increase in mortality within 24 hours, and four-fold increase in total mortality. They concluded that CCTs are weak predictors of bleeding tendencies in the critically ill (14).

Holcomb et al. evaluated a series of 1974 consecutive trauma patients at a Level 1 Trauma Center with a median ISS of 17, 25% of whom presented in shock and 28% of whom were transfused (15). After controlling for age, mechanism, Revised Trauma Score, base excess, and hemoglobin, the authors found that R-time predicted red blood cell transfusion and α angle predicted massive transfusion better than PT or PTT. The α angle was superior to fibrinogen in predicting plasma transfusion, and the MA was superior to platelet count in predicting platelet need. These correlations improved for transfused, shock, or head injured patients. The authors argue that there is little functional information in the CCTs, and the turnaround time is slow in situations where minutes matter.

Schöchel et al. performed a retrospective literature review regarding point-of-care coagulation testing as a means to guide treatment decisions in trauma (16). Conventional plasma-based coagulation testing, such as PT/INR and aPTT failed to fully assess the clotting process. They argued that TEG provides a rapid and dynamic bedside assessment of the initiation and kinetics of clot formation, firmness, and breakdown, unlike CCTs, which do not provide information on these parameters. They cautioned that although TEG-guided transfusion can reduce the amount of bleeding, the use of viscoelastic tests does not reduce morbidity or mortality.

Da Luz et al. performed a descriptive systematic review considering the diagnostic performance of TEG compared to CCT. Current CCTs have limited utility to diagnose early trauma coagulopathies and direct their treatment. The study lacked randomized control trials. They concluded that there is limited, but rapidly growing observational evidence on the use of TEG in trauma (17).

As a test of whole blood coagulation, TEG can be used to guide blood product administration. Using remote tracing software in the emergency department, this can allow rapid decision making early in a patient's resuscitation. In a study of 272 trauma patients, Cotton et al. were able to view R- time and K- time within 5 minutes, and α angle and MA within 15 minutes (18). Conventional coagulation tests were not available for 48 minutes. R time and K time were found to strongly correlate with PT/INR and PTT, whereas MA and α angle were found to strongly correlate with platelet count. Controlling for demographics and emergency department vital signs, R time best predicted the need for massive transfusion in the first 6 hours. These findings were echoed in a recent study of pediatric trauma patients (19).

Tapia et al. evaluated the use of a TEG-guided massive transfusion algorithm before switching to the now common 1:1:1 (pRBC:FFP:platelet) massive transfusion protocol (MTP) (20). TEG-guided resuscitation was equivalent to standardized MTP in patients receiving 6 or more units of pRBC's. However, MTP worsened mortality in penetrating trauma patients receiving 10 or more units of pRBC's. TEG-directed therapy seemed to provide optimal ratios through laboratory data rather than a predefined, ratio-based transfusion practice. Thus, utilization of TEG in conjunction with MTP may help elucidate those patients requiring more aggressive resuscitation because of their unique physiologic response to injury and, inversely, avoid unnecessary transfusion of products when they are not needed.

In a prospective, pragmatic, randomized trial performed at a Level 1 Trauma Center, Gonzalez et al. compared the use of CCT and TEG to direct the resuscitation of severely injured patients (21). Twenty-eight-day survival, the primary outcome, was significantly higher in the TEG group. The amounts of administered crystalloid and RBC were similar between the two groups. The TEG group had significant improvement in survival at 28 days and at 6 hours from injury, while using less plasma and platelets in the early phase of resuscitation compared with the CCT group. They found an MTP goal, directed by TEG, resulted in a survival benefit compared with CCT-guided transfusion. This resulted from less hemorrhagic deaths and less early deaths occurring in the TEG group. MTP based on CCT led to more plasma and platelets transfused in the early phase and more cryoprecipitate transfusion overall. Although the survival benefit was attributable to the first 6 hours from emergency department arrival, survivors in the TEG-guided MTP group also benefited from more ICU-free and ventilator-free days.

An Eastern Association for the Surgery of Trauma (EAST) Practice Management Guideline by Bugaev and colleagues conditionally recommended using TEG-guided transfusions over CCT in adult trauma and surgical patients, and in patients with critical illness (22). This is a conditional recommendation due to the low grade of evidence in the body of literature. Clearly, more research needs to be carried out for this potentially promising method of guided resuscitation.

In a multicenter observational study at 12 Level I and II trauma centers, Neal et al. compared the TEG 5000 and TEG 6s systems for detecting coagulopathy in trauma patients (23). Citrated kaolin reaction time, functional fibrinogen maximum amplitude, percent clot lysis at 30 minutes, RapidTEG maximum amplitude, and maximum amplitude were assessed to determine equivalence between the TEG 5000 and TEG 6s systems. The results between the two systems strongly correlated, indicating the TEG 6s system may be a reliable alternative to the TEG 5000 system when assessing coagulopathy in trauma patients.

REFERENCES

1. Luddington RJ. Thromboelastography/thromboelastometry. *Clin Lab Haematol* 2005; 27:81-90.
2. Subramanian M, Kaplan LJ, Cannon JW. Thromboelastography-guided resuscitation of the trauma patient. *JAMA Surg* 2019;154(12):1152-1153.
3. Wang SC, Shieh JF, Chang KY et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. *Transfusion* 2010; 47:2590-2593.
4. Speiss BD, Gilles BS, Chandler W, et al. Changes in transfusion therapy and re-exploration rate after institution of a blood management program in cardiac surgical patients. *J Cardiothoracic Vasc Anesth* 1995; 9:168-173.
5. Ak K, Isbir CS, Tetik S, et al. Thromboelastography-based transfusion algorithm reduced blood product use after elective CABG: a prospective randomized study. *J Card Surg* 2009; 24:404-410.
6. Niles SE, McLaughlin DF, Perkins JG et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. *J Trauma* 2008; 64:1459-1463.
7. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *J Trauma* 2003; 54:1127-1130.
8. Cotton BA, Gunter OL, Isbell J et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. *J Trauma* 2008; 64:1177-82.
9. Walsh M, Fritz S, Hake D, et al. Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy. *Curr Drug Targets*. 2016; 17(8):954-970.
10. Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. *Ann Surg* 2012; 255:379-385.
11. Cohen MK, Kutcher M, Redick B, et al. Clinical and mechanistic drivers of acute traumatic coagulopathy. *J Trauma Acute Care Surg* 2013; 75:S40-47.
12. Kaufmann CR, Dwyer KM, Crews JD et al. Usefulness of thromboelastography in assessment of trauma patient coagulation. *J Trauma* 1997; 42:716-720.
13. Martini WZ, Cortez DS, Dubick MA, et al. Thromboelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock, and resuscitation in pigs. *J Trauma* 2008; 65:535-543.
14. Lier H, Böttiger BW, Hinkelbein J, Krep H, Bernhard M. Coagulation management in multiple trauma: a systematic review. *Intensive Care Med* 2011; 37(4):572-582.
15. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thromboelastography can replace conventional coagulation tests in the emergency department. *Ann Surg* 2012; 256:476-486.
16. Schöchl H, Voelckel W, Grassetto A, Schlimp CJ. Practical application of point-of-care coagulation testing to guide treatment decisions in trauma. *J Trauma Acute Care Surg* 2013; 74(6):1587-1598.
17. Da Luz LT, Nascimento B, Shankarakutty AK, Rizoli S, Adhikari NK. Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. *Crit Care* 2014; 18(5):518.
18. Cotton BA, Faz G, Hatch QM, et al. Rapid thromboelastography delivers real-time results that predict transfusion within 1 hour of admission. *J Trauma* 2011; 71:407-417.
19. Vogel AM, Radwan ZA, Cox CS, et al. Admission rapid thromboelastography delivers real-time “actionable” data in pediatric trauma. *J Ped Surg* 2013; 48:1371-1376.
20. Tapia NM, Chang A, Norman M, et al. TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients. *J Trauma Acute Care Surg* 2012; 74:378-386.

21. Gonzalez E, Moore EE, Moore HB, et al. goal-directed hemostatic resuscitation of trauma-induced coagulopathy: A pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. *Ann Surg* 2016; 263(6):1051-1059.
22. Bugaev N, Como JJ, Golani G, Freeman JJ, Sawhney JS et al. Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma. *J Trauma Acute Care Surg* 2020; 89(6):999-1017.
23. Neal MD, Moore EE, Walsh M, Thomas S, Callcut RA et al. A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients. *J Trauma Acute Care Surg* 2019; 88(2): 279-285.

Table 1: TEG 5000 values and interpretation

TEG Value	Normal	Description	Measures
R time (conventional)	3 – 8 min	“Reaction time” to initial fibrin formation	clotting factors (intrinsic pathway)
K time	1 - 3 min	“Kinetic time” for fibrin cross linkage to reach 20 mm clot strength	fibrinogen, platelet number
α angle	55 - 78 degrees	Angle from baseline to slope of tracing that represents clot formation	fibrinogen, platelet number
MA	51 – 69 mm	Maximum amplitude of tracing	platelet number and function

Table 2: Suggested TEG 5000-guided transfusion

TEG Value	Transfuse
R time > 8	FFP
K time > 3	cryoprecipitate
α angle < 55	cryoprecipitate +/- platelets
MA < 51	platelets

Table 3: TEG 6s values and interpretation

TEG Value	Normal	Description	Measures
R _{CK} time	4.6 – 9.1 min	“Reaction time” to initial fibrin formation	clotting factors (intrinsic pathway)
MA _{CFF}	15-32 mm	Maximum amplitude of tracing	platelet number and function
MA _{CRT}	52 – 70 mm	Calculated value of clot strength	entire coagulation cascade
LY 30	0 – 2.6%	Clot lysis at 30 minutes following MA	fibrinolysis

Table 4: Suggested TEG 6s-guided transfusion

TEG Value	Transfuse
R _{CK} time > 9.1	FFP
MA _{CFF} < 15	Platelets
MA _{CRT} < 52	Cryoprecipitate +/- Platelets

MASSIVE TRANSFUSION PROTOCOL

